gpt-dict.com

Bifidobacterium longum BB536 for Allergic Rhinitis

Verdict: Published with Warning

Across 6 PubMed studies, the evidence for Bifidobacterium longum BB536 in Allergic Rhinitis grades Tier B — preliminary evidence. Effective, but with safety or population caveats.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.64
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
70%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.75
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.64
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (2 篇 > 1 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

The Efficacy and Safety of Probiotics for Allergic Rhinitis: A Systematic Review and Meta-Analysis
PMID: 35663980 2022 統合分析 n = 1,778
Finding: Probiotics (mixed strains) gave a small significant reduction in TNSS (SMD -0.29, 95% CI -0.44 to -0.13, p=0.0003, I2=89%) and improved RQLQ (SMD -0.64, 95% CI -0.79 to -0.49, p<0.00001, I2=97%) but had no effect on total IgE (SMD -0.03, 95% CI -0.18 to 0.13, p=0.72).
Government Effect size: TNSS SMD -0.29 (95% CI -0.44 to -0.13); RQLQ SMD -0.64 (95% CI -0.79 to -0.49); IgE SMD -0.03 (NS)
View on PubMed
Effects of Probiotics on Allergic Rhinitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
PMID: 35099301 2022 統合分析 n = 1,591
Finding: Pooled per-strain analyses showed no significant reduction in nasal symptom scores for the best-studied strains (L. paracasei Lp33 SMD -1.61, 95% CI -4.67 to 1.45; L. rhamnosus GG SMD -1.00, 95% CI -3.01 to 1.00), though 8 of 9 probiotic types eased at least one symptom; no Bifidobacterium longum BB536-specific pooled estimate was reported.
Mixed funding Effect size: Lp33 SMD -1.61 (95% CI -4.67 to 1.45, NS); LGG SMD -1.00 (95% CI -3.01 to 1.00, NS)
View on PubMed
A Systematic Review and Meta-analysis of Probiotics for the Treatment of Allergic Rhinitis
PMID: 25899251 2015 統合分析 n = 1,919
Finding: Probiotics (mixed strains) significantly improved RQLQ quality of life (SMD -2.23, 95% CI -4.07 to -0.40, p=0.02) but did not significantly reduce total symptom score RTSS (SMD -0.36, 95% CI -0.83 to 0.10, p=0.13); 17 of 23 trials reported benefit on at least one measure.
Academic Effect size: RQLQ SMD -2.23 (95% CI -4.07 to -0.40); RTSS SMD -0.36 (95% CI -0.83 to 0.10, NS)
View on PubMed
Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial
PMID: 17083353 2006 RCT (double-blind) n = 44
Finding: Over 13 weeks, B. longum BB536 significantly reduced rhinorrhea, nasal blockage and composite symptom scores and lowered the number of subjects prematurely withdrawing for severe symptoms/medication (P=0.0057 vs placebo) in Japanese cedar pollinosis adults.
🟠 Limited quality ⚠️ Industry-funded Effect size: Premature termination/medication P=0.0057; significant reductions in rhinorrhea and nasal-blockage scores (p<0.05)
View on PubMed
Effect of probiotic Bifidobacterium longum BB536 in relieving clinical symptoms and modulating plasma cytokine levels of Japanese cedar pollinosis during the pollen season. A randomized double-blind, placebo-controlled trial
PMID: 16689181 2006 RCT (double-blind) n = 40
Finding: BB536-supplemented yoghurt (2x100 g/day) over 14 weeks significantly alleviated eye symptoms versus placebo (odds ratio 0.31, 95% CI 0.10-0.97, p=0.044), with a modulating effect on Th1/Th2 balance, in Japanese cedar pollinosis adults.
🟠 Limited quality ⚠️ Industry-funded Effect size: Eye symptoms OR 0.31 (95% CI 0.10-0.97, p=0.044)
View on PubMed
Bifidobacterium mixture (B longum BB536, B infantis M-63, B breve M-16V) treatment in children with seasonal allergic rhinitis and intermittent asthma
PMID: 28270216 2017 RCT (double-blind) n = 40
Finding: A 3-strain Bifidobacterium mixture containing BB536 (BB536 3x10^9 + M-63 1x10^9 + M-16V 1x10^9 CFU/day) for 4 weeks significantly improved AR symptoms (p<0.005) and QoL (p<0.001) versus placebo, but BB536's individual contribution cannot be isolated from the mixture.
🟠 Limited quality Effect size: Symptoms p<0.005; QoL p<0.001 (mixture vs placebo; no isolated BB536 effect size)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
GRN No. 877 — Bifidobacterium longum BB536. Intended use: ingredient in term infant formula at a level of 1 x 10^8 CFU per gram of product. FDA closure date: December 26, 2019. FDA letter: 'FDA has no questions' regarding the safety of Bifidobacterium longum BB536 when used as described in the notice. (Earlier GRN 268 covered use in conventional foods/beverages.) source↗
L4b EU EFSA
Cautious
Scientific Opinion on the substantiation of health claims related to Bifidobacterium longum BB536 and improvement of bowel regularity (ID 3004), normal resistance to cedar pollen allergens (ID 3006), and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 3005) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. Conclusion: Bifidobacterium longum BB536 does not improve… source↗
L4d TW TFDA / 衛福部
Neutral
健康食品查驗登記審查採雙軌制，第一軌為「個案審查」，第二軌為「規格標準審查」，通過審查的產品會給予健康食品(小綠人)標章，第一軌的產品上標有「衛部健食字第A00000號」，第二軌的產品標有「衛部健食規字第000000號」。目前健康食品可以宣稱的保健功效項目共有13項，包括調節血脂、胃腸功能改善、護肝、免疫調節、骨質保健、不易形成體脂肪、抗疲勞、輔助調整過敏體質、調節血糖、延緩衰老、牙齒保健、促進鐵吸收、輔助調節血壓。 source↗
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-allergic-rhinitis-INT-bifidobacterium-longum-bb536-001 繁體中文版 →